Takeda Pharmaceutical (TKPHF) Debt to Equity (2018 - 2026)

Takeda Pharmaceutical's Debt to Equity history runs 9 years deep, the most recent figure standing at $0.64 for Q1 2026.

• In Q1 2026, Debt to Equity fell 2.42% year-over-year to $0.64; the TTM figure through Mar 2026 stood at $0.64 (down 2.42% YoY), while the FY2026 annual figure was $0.64, down 2.42% from the prior year.
• Debt to Equity was $0.64 for Q1 2026 at Takeda Pharmaceutical, roughly flat from $0.63 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.76 in Q2 2022 to a low of $0.11 in Q1 2024.
• Historically, Debt to Equity has averaged $0.62 across 5 years, with a median of $0.69 in 2023.
• The sharpest annual moves came in 2023 and 2024: Debt to Equity soared 489.61% in 2023, then plunged 83.43% in 2024.
• A 5-year view of Debt to Equity shows it stood at $0.72 in 2022, then climbed by 0.26% to $0.72 in 2023, then slipped by 0.48% to $0.71 in 2024, then slipped by 11.32% to $0.63 in 2025, then rose by 0.39% to $0.64 in 2026.
• The last three Debt to Equity figures came in at $0.64 (Q1 2026), $0.63 (Q4 2025), and $0.69 (Q3 2025), per Business Quant data.